Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

685 Route 202/206 N, Suite 301, Bridgewater, United States

Maldoi Oct. 25 at 5:01 AM

$VYNE I bought some shares cause looks way under cash value. As per Finviz. Cash/sh 1.56 Book/sh 1.97

0 · Reply

PS600REVX Oct. 24 at 3:46 PM

$VYNE 30 mill ish float? And Volume is always above 1 mill. Plenty of liquidity. Somebody working hard to keep this down for now. Chilling with my reentry at 345 after selling on last run to 44. Looking for way more this time. It's coming

1 · Reply

Jlloyd31 Oct. 24 at 3:36 PM

$VYNE took a starter. .375. Will add if volume comes in

0 · Reply

hiTHit Oct. 24 at 3:36 PM

$VYNE Whatever the crowd on the board does and says is right.

1 · Reply

mark31 Oct. 24 at 2:45 PM

$VYNE

0 · Reply

mark31 Oct. 24 at 1:58 PM

$VYNE trading way under cash here will get found

0 · Reply

nonamestockz Oct. 23 at 8:04 PM

$VYNE still super bullish here like $VCIG

0 · Reply

hiTHit Oct. 23 at 3:50 PM

$VYNE Some of them can be extremely bullish on one board and extremely bearish on another. What kind of fantasy do these friends have?🤓

0 · Reply

SumDay1Day Oct. 23 at 2:05 PM

$VYNE getting back in the .40s will be good for a positive turn. $USEG ending above 1.50 today sets us up for a nice run off these oil plays. $OFAL back above 1$ and gaining momentum to stay there. $YYAI Yall got bent over. 😳 I hope some of you set a SL and or get some money back in the next week. Played it fron .10 to .15 and got out of dodge. Lets end today and tomorrow with a bang into next week.

0 · Reply

Goingforthe10bagger Oct. 22 at 10:23 PM

$VYNE I just keep buying, buying and buying. I’m up to 547,000 shares. My goal is to get to 600,000 shares by the end of October. I love investing in stocks that have more cash on the books then the market cap of the company. It helps me sleep at night.

1 · Reply

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Jul 30, 2025, 8:00 AM EDT - 3 months ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 2, 2025, 7:45 AM EDT - 4 months ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

May 8, 2025, 8:00 AM EDT - 6 months ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Apr 25, 2025, 11:55 AM EDT - 6 months ago

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 8:00 AM EDT - 6 months ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 20, 2025, 8:00 AM EDT - 7 months ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics to Participate in March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Jan 6, 2025, 7:30 AM EST - 10 months ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 10 months ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 26, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 1 year ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 1 year ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI IBIO

Jan 10, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 2 years ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 2 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 2 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 2 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 18, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 2 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:00 PM EST - 2 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

Feb 10, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Reverse Stock Split

Jan 9, 2023, 4:01 PM EST - 3 years ago

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

Dec 12, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

Dec 7, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

Dec 2, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Maldoi Oct. 25 at 5:01 AM

$VYNE I bought some shares cause looks way under cash value. As per Finviz. Cash/sh 1.56 Book/sh 1.97

0 · Reply

PS600REVX Oct. 24 at 3:46 PM

1 · Reply

Jlloyd31 Oct. 24 at 3:36 PM

$VYNE took a starter. .375. Will add if volume comes in

0 · Reply

hiTHit Oct. 24 at 3:36 PM

$VYNE Whatever the crowd on the board does and says is right.

1 · Reply

mark31 Oct. 24 at 2:45 PM

$VYNE

0 · Reply

mark31 Oct. 24 at 1:58 PM

$VYNE trading way under cash here will get found

0 · Reply

nonamestockz Oct. 23 at 8:04 PM

$VYNE still super bullish here like $VCIG

0 · Reply

hiTHit Oct. 23 at 3:50 PM

$VYNE Some of them can be extremely bullish on one board and extremely bearish on another. What kind of fantasy do these friends have?🤓

0 · Reply

SumDay1Day Oct. 23 at 2:05 PM

0 · Reply

Goingforthe10bagger Oct. 22 at 10:23 PM

1 · Reply

CashtyNashty Oct. 22 at 9:59 PM

$VYNE impressive to have this price to go with the bid/ask action. 😂. Fraud street keeps it fun.

0 · Reply

Natedogee Oct. 22 at 4:17 PM

$VYNE thinking I need to accept defeat and create a stop loss

3 · Reply

hiTHit Oct. 22 at 3:54 PM

$VYNE Long live noble poverty!

1 · Reply

gifor Oct. 22 at 3:23 PM

$VYNE done

0 · Reply

CashtyNashty Oct. 22 at 2:56 PM

$VYNE love this stock and the manipulation to try and acquire the limited shares. 500k of volume to move it up $.015 and 40k to drop it $.02. 😂

0 · Reply

mark31 Oct. 22 at 2:07 PM

$VYNE

0 · Reply

mark31 Oct. 22 at 1:59 PM

$VYNE CHEAP here bio's do good in nov

0 · Reply

revueltoL Oct. 21 at 9:27 PM

$VYNE willing to bet patience from these levels will be overwhelmingly rewarding..

1 · Reply

notsurewhat Oct. 21 at 5:43 PM

$VYNE gettin tired of waiting here lol hopefully a nice update soon!!

1 · Reply

Natedogee Oct. 21 at 3:48 PM

$VYNE

1 · Reply

mark31 Oct. 21 at 2:59 PM

$VYNE added more .37

1 · Reply

nonamestockz Oct. 20 at 8:19 PM

$VYNE I like the charting - 70s is easy to reach - just a matter of time

1 · Reply

Market Cap	9.42M
Revenue (ttm)	500,000.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,966.00%
Debt to Equity Ratio	0.00

Volume	855,900
Avg Vol	2,361,076
Day's Range	N/A - N/A
Shares Out	25.47M
Stochastic %K	52%
Beta	1.91
Analysts	Sell
Price Target	$2.00